EYETEC research group conducts translational research in eye diseases, with a particular focus on uveal melanoma. In line with the vision of Oslo University Hospital (OUS), “Our research shall provide knowledge – for the benefit of the patients,” the group aims to generate new knowledge that can be translated into improved diagnostics, prognostication, treatment, and prevention of eye diseases.

Our research combines molecular biology, bioinformatics, and clinical research to elucidate disease mechanisms, identify clinically relevant biomarkers and therapeutic targets, and develop more precise and effective approaches to patient care. A central goal is to bridge the gap between basic molecular discoveries and clinical implementation, ensuring that new biological insights can ultimately benefit patients.

The research programme in uveal melanoma includes studies of genetic and epigenetic alterations, tumour biology, and mechanisms underlying tumour progression and treatment response. State-of-the-art technologies, including CRISPR-based approaches, single-cell and spatial transcriptomics, are used to characterise tumour heterogeneity and identify molecular mechanisms and potential therapeutic targets. The group also investigates minimally invasive biomarkers, including circulating tumour DNA (ctDNA) and extracellular vesicles, with the aim of improving diagnosis, risk stratification, treatment monitoring, and detection of disease progression.

In parallel, the group develops research within improved diagnostic methods, regenerative medicine, and tissue engineering for other eye diseases. By integrating advanced molecular technologies with clinical expertise and patient-oriented research, the group seeks to contribute to more personalised, targeted, and effective treatment strategies and to strengthen the translation of innovative research into clinical practice.

Overall, the group’s research is driven by a clear translational ambition: to transform new knowledge about the molecular mechanisms of eye disease into better diagnostics, prognostic tools, and treatments that improve outcomes for patients.